#CNS therapeutics

Eli Lilly’s $6.3B Centessa Deal Signals Sleep Drug Race

Eli Lilly is reportedly acquiring sleep-drug maker Centessa for $6.3B, underscoring how aggressively big pharma is moving to secure differentiated CNS and sleep...